1072902-75-0

Basic information

• Product Name: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester
• Synonyms: L-Isoleucine Orlistat;N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester;Orlistat USP Related Compound E
• CAS NO: 1072902-75-0
• Molecular Formula: C29H53NO5
• Molecular Weight: 495.73482
• Product Categories: Chiral Reagents;Impurities;Intermediates & Fine Chemicals;Pharmaceuticals;Chiral Reagents, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 1072902-75-0.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(CAS DataBase Reference)
• NIST Chemistry Reference: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(1072902-75-0)
• EPA Substance Registry System: N-ForMyl-L-isoleucine (1S)-1-[[(2S,3S)-3-Hexyl-4-oxo-2-oxetanyl]Methyl]dodecyl Ester(1072902-75-0)

Safety Data

• Hazardous Substances Data: 1072902-75-0(Hazardous Substances Data)

Usage

Uses

Different sources of media describe the Uses of 1072902-75-0 differently. You can refer to the following data:
1. L-Isoleucine Orlistat is an impurity of Orlistat (O686500). Also, L-Isoleucine Orlistat is a Tetrahydrolipstatin (THL) analogue as inhibitor of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG).
2. L-Isoleucine Orlistat is an impurity of Orlistat (O686500). Also, L-Isoleucine Orlistat is a Tetrahydrolipstatin (THL) analogue as inhibitor of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG).

Upstream product

• 1558-67-4 formic anhydride 
• 104871-99-0 (3S,4S)-3-hexyl-4-[(2S)-2-hydroxytridecyl]oxetan-2-one 
• 3160-59-6 N-Cbz-L-Isoleucine 
• 73-32-5 L-isoleucine 
• 1072902-95-4 L-isoleucine-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester 
• 1072902-88-5 N-[(phenylmethoxy)carbonyl]-L-isoleucine-(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester 
• 2258-42-6 formyl acetic anhydride 

Relevant articles and documents

NOVEL LIPASE INHIBITORS, REPORTER SUBSTRATES AND USES THEREOF

The invention provides for novel lipase inhibitors, and compositions and devices comprising the same. The invention further provides for methods for treatment o f disorders comprising administration o f novel diacylglycerol lipase inhibitors, and com -positions and devices comprising said inhibitors. In some embodiments, the disorders are pancreatitis, obesity, shock or pancreatic necrosis. The invention further provides for novel ether lipid reporter compounds and methods o f assaying enzymatic activity com -prising contacting a compound with a novel ether lipid reporter compound.

Tetrahydrolipstatin analogues as modulators of endocannabinoid 2-arachidonoylglycerol metabolism

A series of 21 analogues of tetrahydrolipstatin (THL, 1) were synthesized and tested as inhibitors of the formation or hydrolysis of the endocannabinoid 2-arachidonoylglycerol (2-AG). Three of the novel compounds, i.e., 11, 13, and 15, inhibited 2-AG formation via the diacylglycerol lipase α (DAGLα) with IC50 values lower than 50 nM (IC50 of THL = 1 μM) and were between 23- and 375-fold selective vs 2-AG hydrolysis by monoacylglycerol lipase (MAGL) as well as vs cannabinoid CB1 and CB2 receptors and anandamide hydrolysis by fatty acid amide hydrolase (FAAH). Three other THL analogues, i.e., 14, 16, and 18, were slightly more potent than THL against DAGLα and appreciably selective vs MAGL, CB receptors, and FAAH (15-26-fold). One compound, i.e., 8, was a potent inhibitor of MAGL-like activity (IC50 = 0.41 μM), and relatively (～7-fold) selective vs the other targets tested.